- Fionet Rapid Response Group (FRR) have reached an agreement with the Rwanda Ministry of Health to deploy the Fionet Platform for the containment of Rwanda’s malaria epidemic
- Rwanda Ministry of Health will pay over C$750,000 to FRR to pilot the Fionet Platform for six months
- If successful, this pilot is expected to lead to a country-wide deployment, which could scale to a nationwide program
- The Fionet Platform is an end-to-end, rapid testing and tracking solution that enhances the quality of healthcare delivered in decentralized settings
- Relay Medical is a technology innovator focused on the development of novel solutions in the diagnostics, AI data science and IoT security sectors
- Relay Medical Corp. (RELA) is up 2.17 per cent, trading at C$0.235 per share at 4:30 pm ET
Relay (RELA) & Fio through their joint venture, Fionet Rapid Response Group (FRR) have reached an agreement with the Rwanda Ministry of Health.
Under the terms of the agreement, FRR will deploy the Fionet Platform for the containment of Rwanda’s malaria epidemic.
The parties are finalizing the details of the deployment under which the Rwanda Ministry of Health will pay over C$750,000 to FRR to pilot the Fionet Platform for six months.
If successful, this pilot is expected to lead to a country-wide deployment, which could scale to a nationwide program. Funding will be provided to the Rwanda Ministry of Health from a world-leading US-based charitable foundation.
Malaria kills over 400,000 people annually, two-thirds of whom are children under the age of five. Rwanda is in the top 25 countries in the world with the highest number of malaria cases and deaths.
Donors such as USAID, Bill and Melinda Gates Foundation, and the Global Fund, spend $3.5 billion annually on malaria control programs.
“Our work with USAID in Central Africa has attracted interest for our Fionet Platform, including from Rwanda Ministry of Health,” said Dr. Michael Greenberg, CEO of FRR.
“Fionet’s capability to test and track diseases like malaria or COVID-19 across diverse countries is a valuable asset for any healthcare system. Through decentralized real-time data collection and aggregation, Fionet can provide healthcare officials with actionable insights working to contain current and future pandemics.”
Fionet has proven to be a reliable rapid diagnostic testing solution during the outbreak of the COVID-19 pandemic. Prior to COVID-19, Fionet was successfully used to test and track over one million patients in remote settings around the world for infectious diseases including Ebola, HIV and dengue fever.
The Fionet Platform is an end-to-end, rapid testing and tracking solution that enhances the quality of healthcare delivered in decentralized health centers, health posts, and communities. Fionet Portals allow off-site supervisors to track and direct frontline action, displaying accurate epidemiological information and providing actionable insights.
In other news, Relay Medical has granted 500,000 share purchase options to certain officers, directors and consultants.
Relay Medical is a technology innovator focused on the development of novel solutions in the diagnostics, AI data science and IoT security sectors.
Relay Medical Corp. (RELA) is up 2.17 per cent, trading at C$0.235 per share at 4:30 pm ET.
